Copeptin Serum Level in Liver Transplant Recipients

Liver Cirrhosis Clinical Trial

Official title:

Copeptin Serum Level in Liver Transplant Recipients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03587623
• Other study ID #: Livercopeptin
• Status: Completed
• Start date: July 4, 2018
• Est. completion date: January 31, 2020

Study information

• Verified date: August 2020
• Source: Medical University of Warsaw
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study aim is to measure perioperative copeptin concentration in blood of liver transplant recipients and to assess whether there is a correlation between its level and hemodynamic derangement.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 38
• Est. completion date: January 31, 2020
• Est. primary completion date: January 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient undergoing liver transplantation

Exclusion Criteria:

• Serum creatinine > 1,5 mg/dl

• Retransplantation

• Patient refusal

• CRRT or dialysis preoperatively

Related Conditions & MeSH terms

• Copeptin
• Diabetes Insipidus
• Liver Cirrhosis
• Liver Transplant

Locations

Country	Name	City	State
Poland	I Klinika Anestezjologii WUM	Warsaw	Mazovian Voivodeship

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Warsaw

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum Copeptin concentration		Baseline, intraoperatively, 1,3,7,21 day postoperatively